Novel Antibacterial Class

Peter J. Dandliker, Steve D. Pratt, Angela M. Nilius, Candace Black-Schaefer, Xiaoan Ruan, Danli L. Towne, Richard F. Clark, Erika E. Englund, Rolf Wagner, Moshe Weitzberg, Linda E. Chovan, Robert K. Hickman, Melissa M. Daly, Stephan Kakavas, Ping Zhong, Zhensheng Cao, Caroline A. David, Xiaoling Xuei, Claude G. Lerner, Niru B. SoniMai Bui, Linus L. Shen, Yingna Cai, Philip J. Merta, Anne Y C Saiki, Bruce A. Beutel

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

We report the discovery and characterization of a novel ribosome inhibitor (NRI) class that exhibits selective and broad-spectrum antibacterial activity. Compounds in this class inhibit growth of many gram-positive and gram-negative bacteria, including the common respiratory pathogens Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, and Moraxella catarrhalis, and are nontoxic to human cell lines. The first NRI was discovered in a high-throughput screen designed to identify inhibitors of cell-free translation in extracts from S. pneumoniae. The chemical structure of the NRI class is related to antibacterial quinolones, but, interestingly, the differences in structure are sufficient to completely alter the biochemical and intracellular mechanisms of action. Expression array studies and analysis of NRI-resistant mutants confirm this difference in intracellular mechanism and provide evidence that the NRIs inhibit bacterial protein synthesis by inhibiting ribosomes. Furthermore, compounds in the NRI series appear to inhibit bacterial ribosomes by a new mechanism, because NRI-resistant strains are not cross-resistant to other ribosome inhibitors, such as macrolides, chloramphenicol, tetracycline, aminoglycosides, or oxazolidinones. The NRIs are a promising new antibacterial class with activity against all major drug-resistant respiratory pathogens.

Original languageEnglish (US)
Pages (from-to)3831-3839
Number of pages9
JournalAntimicrobial Agents and Chemotherapy
Volume47
Issue number12
DOIs
StatePublished - Dec 2003
Externally publishedYes

Fingerprint

Ribosomes
Streptococcus pneumoniae
Oxazolidinones
Moraxella (Branhamella) catarrhalis
Bacterial Proteins
Quinolones
Macrolides
Haemophilus influenzae
Aminoglycosides
Chloramphenicol
Tetracycline
Gram-Negative Bacteria
Staphylococcus aureus
Cell Line
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Dandliker, P. J., Pratt, S. D., Nilius, A. M., Black-Schaefer, C., Ruan, X., Towne, D. L., ... Beutel, B. A. (2003). Novel Antibacterial Class. Antimicrobial Agents and Chemotherapy, 47(12), 3831-3839. https://doi.org/10.1128/AAC.47.12.3831-3839.2003

Novel Antibacterial Class. / Dandliker, Peter J.; Pratt, Steve D.; Nilius, Angela M.; Black-Schaefer, Candace; Ruan, Xiaoan; Towne, Danli L.; Clark, Richard F.; Englund, Erika E.; Wagner, Rolf; Weitzberg, Moshe; Chovan, Linda E.; Hickman, Robert K.; Daly, Melissa M.; Kakavas, Stephan; Zhong, Ping; Cao, Zhensheng; David, Caroline A.; Xuei, Xiaoling; Lerner, Claude G.; Soni, Niru B.; Bui, Mai; Shen, Linus L.; Cai, Yingna; Merta, Philip J.; Saiki, Anne Y C; Beutel, Bruce A.

In: Antimicrobial Agents and Chemotherapy, Vol. 47, No. 12, 12.2003, p. 3831-3839.

Research output: Contribution to journalArticle

Dandliker, PJ, Pratt, SD, Nilius, AM, Black-Schaefer, C, Ruan, X, Towne, DL, Clark, RF, Englund, EE, Wagner, R, Weitzberg, M, Chovan, LE, Hickman, RK, Daly, MM, Kakavas, S, Zhong, P, Cao, Z, David, CA, Xuei, X, Lerner, CG, Soni, NB, Bui, M, Shen, LL, Cai, Y, Merta, PJ, Saiki, AYC & Beutel, BA 2003, 'Novel Antibacterial Class', Antimicrobial Agents and Chemotherapy, vol. 47, no. 12, pp. 3831-3839. https://doi.org/10.1128/AAC.47.12.3831-3839.2003
Dandliker PJ, Pratt SD, Nilius AM, Black-Schaefer C, Ruan X, Towne DL et al. Novel Antibacterial Class. Antimicrobial Agents and Chemotherapy. 2003 Dec;47(12):3831-3839. https://doi.org/10.1128/AAC.47.12.3831-3839.2003
Dandliker, Peter J. ; Pratt, Steve D. ; Nilius, Angela M. ; Black-Schaefer, Candace ; Ruan, Xiaoan ; Towne, Danli L. ; Clark, Richard F. ; Englund, Erika E. ; Wagner, Rolf ; Weitzberg, Moshe ; Chovan, Linda E. ; Hickman, Robert K. ; Daly, Melissa M. ; Kakavas, Stephan ; Zhong, Ping ; Cao, Zhensheng ; David, Caroline A. ; Xuei, Xiaoling ; Lerner, Claude G. ; Soni, Niru B. ; Bui, Mai ; Shen, Linus L. ; Cai, Yingna ; Merta, Philip J. ; Saiki, Anne Y C ; Beutel, Bruce A. / Novel Antibacterial Class. In: Antimicrobial Agents and Chemotherapy. 2003 ; Vol. 47, No. 12. pp. 3831-3839.
@article{ac726d50bf1d4fb4a2cf344d7c0ba44a,
title = "Novel Antibacterial Class",
abstract = "We report the discovery and characterization of a novel ribosome inhibitor (NRI) class that exhibits selective and broad-spectrum antibacterial activity. Compounds in this class inhibit growth of many gram-positive and gram-negative bacteria, including the common respiratory pathogens Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, and Moraxella catarrhalis, and are nontoxic to human cell lines. The first NRI was discovered in a high-throughput screen designed to identify inhibitors of cell-free translation in extracts from S. pneumoniae. The chemical structure of the NRI class is related to antibacterial quinolones, but, interestingly, the differences in structure are sufficient to completely alter the biochemical and intracellular mechanisms of action. Expression array studies and analysis of NRI-resistant mutants confirm this difference in intracellular mechanism and provide evidence that the NRIs inhibit bacterial protein synthesis by inhibiting ribosomes. Furthermore, compounds in the NRI series appear to inhibit bacterial ribosomes by a new mechanism, because NRI-resistant strains are not cross-resistant to other ribosome inhibitors, such as macrolides, chloramphenicol, tetracycline, aminoglycosides, or oxazolidinones. The NRIs are a promising new antibacterial class with activity against all major drug-resistant respiratory pathogens.",
author = "Dandliker, {Peter J.} and Pratt, {Steve D.} and Nilius, {Angela M.} and Candace Black-Schaefer and Xiaoan Ruan and Towne, {Danli L.} and Clark, {Richard F.} and Englund, {Erika E.} and Rolf Wagner and Moshe Weitzberg and Chovan, {Linda E.} and Hickman, {Robert K.} and Daly, {Melissa M.} and Stephan Kakavas and Ping Zhong and Zhensheng Cao and David, {Caroline A.} and Xiaoling Xuei and Lerner, {Claude G.} and Soni, {Niru B.} and Mai Bui and Shen, {Linus L.} and Yingna Cai and Merta, {Philip J.} and Saiki, {Anne Y C} and Beutel, {Bruce A.}",
year = "2003",
month = "12",
doi = "10.1128/AAC.47.12.3831-3839.2003",
language = "English (US)",
volume = "47",
pages = "3831--3839",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - Novel Antibacterial Class

AU - Dandliker, Peter J.

AU - Pratt, Steve D.

AU - Nilius, Angela M.

AU - Black-Schaefer, Candace

AU - Ruan, Xiaoan

AU - Towne, Danli L.

AU - Clark, Richard F.

AU - Englund, Erika E.

AU - Wagner, Rolf

AU - Weitzberg, Moshe

AU - Chovan, Linda E.

AU - Hickman, Robert K.

AU - Daly, Melissa M.

AU - Kakavas, Stephan

AU - Zhong, Ping

AU - Cao, Zhensheng

AU - David, Caroline A.

AU - Xuei, Xiaoling

AU - Lerner, Claude G.

AU - Soni, Niru B.

AU - Bui, Mai

AU - Shen, Linus L.

AU - Cai, Yingna

AU - Merta, Philip J.

AU - Saiki, Anne Y C

AU - Beutel, Bruce A.

PY - 2003/12

Y1 - 2003/12

N2 - We report the discovery and characterization of a novel ribosome inhibitor (NRI) class that exhibits selective and broad-spectrum antibacterial activity. Compounds in this class inhibit growth of many gram-positive and gram-negative bacteria, including the common respiratory pathogens Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, and Moraxella catarrhalis, and are nontoxic to human cell lines. The first NRI was discovered in a high-throughput screen designed to identify inhibitors of cell-free translation in extracts from S. pneumoniae. The chemical structure of the NRI class is related to antibacterial quinolones, but, interestingly, the differences in structure are sufficient to completely alter the biochemical and intracellular mechanisms of action. Expression array studies and analysis of NRI-resistant mutants confirm this difference in intracellular mechanism and provide evidence that the NRIs inhibit bacterial protein synthesis by inhibiting ribosomes. Furthermore, compounds in the NRI series appear to inhibit bacterial ribosomes by a new mechanism, because NRI-resistant strains are not cross-resistant to other ribosome inhibitors, such as macrolides, chloramphenicol, tetracycline, aminoglycosides, or oxazolidinones. The NRIs are a promising new antibacterial class with activity against all major drug-resistant respiratory pathogens.

AB - We report the discovery and characterization of a novel ribosome inhibitor (NRI) class that exhibits selective and broad-spectrum antibacterial activity. Compounds in this class inhibit growth of many gram-positive and gram-negative bacteria, including the common respiratory pathogens Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, and Moraxella catarrhalis, and are nontoxic to human cell lines. The first NRI was discovered in a high-throughput screen designed to identify inhibitors of cell-free translation in extracts from S. pneumoniae. The chemical structure of the NRI class is related to antibacterial quinolones, but, interestingly, the differences in structure are sufficient to completely alter the biochemical and intracellular mechanisms of action. Expression array studies and analysis of NRI-resistant mutants confirm this difference in intracellular mechanism and provide evidence that the NRIs inhibit bacterial protein synthesis by inhibiting ribosomes. Furthermore, compounds in the NRI series appear to inhibit bacterial ribosomes by a new mechanism, because NRI-resistant strains are not cross-resistant to other ribosome inhibitors, such as macrolides, chloramphenicol, tetracycline, aminoglycosides, or oxazolidinones. The NRIs are a promising new antibacterial class with activity against all major drug-resistant respiratory pathogens.

UR - http://www.scopus.com/inward/record.url?scp=10744232512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744232512&partnerID=8YFLogxK

U2 - 10.1128/AAC.47.12.3831-3839.2003

DO - 10.1128/AAC.47.12.3831-3839.2003

M3 - Article

C2 - 14638491

AN - SCOPUS:10744232512

VL - 47

SP - 3831

EP - 3839

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 12

ER -